AstraZeneca set out to lead a bold new movement in the fight against amyloidosis, which is a rare, often overlooked cause of heart failure. But leadership knew science alone wouldn’t be enough. The brand behind their evidence development program needed to do more than inform; it needed to awaken belief, unite global collaborators, and inspire confidence across clinical audiences.